within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A03A_DrugsForFunctionalGastrointestinalDisorders.A03AB18_PrifiniumBromide;

model PrifiniumBromide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.05,
    Cl = 1.2638888888888889e-06,
    adminDuration = 600,
    adminMass = 15 / 1000000,
    adminCount = 1,
    Vd = 0.0012,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008333333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>PrifiniumBromide</td></tr><tr><td>ATC code:</td><td>A03AB18</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>15</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.2</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.065</td><td>L/kg/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Prifinium bromide is an anticholinergic agent that acts as a muscarinic receptor antagonist, previously used to relieve gastrointestinal spasms, irritable bowel syndrome, and related motility disorders. It is no longer widely approved or used in many countries today.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed primary literature found reporting human pharmacokinetic parameters of prifinium bromide. The following values are estimated using class-consensus and physicochemical property-based prediction (see notes).</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A03AB18 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end PrifiniumBromide;
